Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Bladder cancer

Advancing perioperative care in MIBC: insights from NIAGARA

Nature Reviews Urology volume 22, pages 412–413 (2025)Cite this article

Subjects

The results of the NIAGARA trial have considerably advanced treatment for patients with muscle-invasive bladder cancer, establishing a new therapeutic standard for cisplatin-eligible patients. Future trials will help to answer remaining questions about perioperative treatment optimization.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Porter, M. P., Kerrigan, M. C., Donato, B. M. K. & Ramsey, S. D. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol. Oncol. 29, 252–258 (2011).

    Article  PubMed  Google Scholar 

  2. Yin, M. et al. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist 21, 708–715 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Powles, T. et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N. Engl. J. Med. 391, 1773–1786 (2024).

    Article  CAS  PubMed  Google Scholar 

  4. Galsky, M. D. et al. Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer. Cell Rep. Med. 5, 101393 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Sritharan, S. & Sivalingam, N. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci. 278, 119527 (2021).

    Article  CAS  PubMed  Google Scholar 

  6. Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102–2114 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Larkins, E. A phase III study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable stage II/III non-small cell lung cancer (AEGEAN): contribution of treatment phase in perioperative trials (FDA, 2024).

  8. Sammarco, E. et al. Immune checkpoint inhibitor rechallenge in renal cell carcinoma: current evidence and future directions. Cancers 15, 3172 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

    Stephan Brönimann & Shahrokh F. Shariat

  2. Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria

    Shahrokh F. Shariat

  3. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic

    Shahrokh F. Shariat

  4. Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA

    Shahrokh F. Shariat

  5. Department of Urology, Weill Cornell Medical College, New York, NY, USA

    Shahrokh F. Shariat

  6. Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan

    Shahrokh F. Shariat

  7. Department of Urology, Semmelweis University, Budapest, Hungary

    Shahrokh F. Shariat

  8. Research Center for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran

    Shahrokh F. Shariat

Authors
  1. Stephan Brönimann
    View author publications

    Search author on:PubMed Google Scholar

  2. Shahrokh F. Shariat
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Shahrokh F. Shariat.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brönimann, S., Shariat, S.F. Advancing perioperative care in MIBC: insights from NIAGARA. Nat Rev Urol 22, 412–413 (2025). https://doi.org/10.1038/s41585-025-01009-7

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41585-025-01009-7

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing